Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068892 | 0.92 | SSTR4 (0.40) | PAX8SSTR4HDAC3HDAC1HDAC2 | |
| SCHEMBL5068866 | 0.90 | PAX8 (0.34) | PAX8SSTR4HDAC3HDAC1HDAC2 | |
| SCHEMBL5064760 | 0.89 | PAX8 (0.33) | PAX8SSTR4HDAC3HDAC1HDAC2 | |
| SCHEMBL5067502 | 0.88 | IKBKB (0.38) | PAX8SSTR4HDAC3HDAC1HDAC2 | |
| SCHEMBL5061163 | 0.83 | SSTR4 (0.37) | PAX8SSTR4HDAC1 | |
| SCHEMBL14032002 | 0.82 | PPARA (0.34) | PAX8 | |
| SCHEMBL5064178 | 0.80 | IKBKB (0.34) | PAX8HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL25737173 | 0.71 | HDAC3 (0.51) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL5065400 | 0.68 | IKBKB (0.44) | PAX8 | |
| SCHEMBL30577124 | 0.64 | HDAC1 (0.43) | SSTR4HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | PAX8 2373/4885SSTR4 432/4885HDAC3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.